Umicore Valuation
Is UMI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UMI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UMI (€10.57) is trading above our estimate of fair value (€1.15)
Significantly Below Fair Value: UMI is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UMI?
Key metric: As UMI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is UMI's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | €15.72b |
| Market Cap | €2.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | 6.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does UMI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
LNZ Lenzing | 0.4x | 2.7% | €1.2b |
WIE Wienerberger | 0.7x | 6.8% | €3.0b |
VOE Voestalpine | 0.2x | 0.7% | €3.2b |
MMK Mayr-Melnhof Karton | 0.4x | 3.5% | €1.4b |
UMI Umicore | 0.2x | -37.1% | €2.5b |
Price-To-Sales vs Peers: UMI is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.4x).
Price to Sales Ratio vs Industry
How does UMI's PS Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Sales vs Industry: UMI is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is UMI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 0.08x |
Price-To-Sales vs Fair Ratio: UMI is expensive based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €10.57 | €14.15 +33.8% | 19.3% | €20.00 | €10.00 | n/a | 17 |
| Nov ’25 | €11.22 | €14.79 +31.9% | 17.3% | €20.00 | €10.00 | n/a | 17 |
| Oct ’25 | €11.81 | €14.85 +25.8% | 16.5% | €20.00 | €11.00 | n/a | 17 |
| Sep ’25 | €11.46 | €15.16 +32.3% | 17.3% | €20.00 | €11.00 | n/a | 17 |
| Aug ’25 | €12.74 | €15.73 +23.5% | 19.3% | €22.00 | €11.00 | n/a | 17 |
| Jul ’25 | €14.25 | €17.46 +22.6% | 24.9% | €29.00 | €13.00 | n/a | 17 |
| Jun ’25 | €18.09 | €21.97 +21.5% | 16.1% | €29.00 | €16.50 | n/a | 17 |
| May ’25 | €20.98 | €24.39 +16.2% | 22.0% | €40.00 | €18.00 | n/a | 18 |
| Apr ’25 | €20.17 | €24.81 +23.0% | 21.0% | €40.00 | €18.00 | n/a | 18 |
| Mar ’25 | €19.39 | €26.18 +35.0% | 25.6% | €46.00 | €18.00 | n/a | 20 |
| Feb ’25 | €21.06 | €27.15 +28.9% | 22.8% | €46.00 | €20.00 | n/a | 20 |
| Jan ’25 | €25.01 | €29.54 +18.1% | 22.2% | €50.00 | €21.00 | n/a | 20 |
| Dec ’24 | €24.80 | €29.84 +20.3% | 21.2% | €50.00 | €22.00 | n/a | 20 |
| Nov ’24 | €22.46 | €30.44 +35.5% | 21.2% | €50.00 | €22.00 | €11.22 | 20 |
| Oct ’24 | €21.74 | €30.89 +42.1% | 19.0% | €50.00 | €22.00 | €11.81 | 20 |
| Sep ’24 | €24.07 | €31.04 +29.0% | 19.2% | €50.00 | €22.00 | €11.46 | 19 |
| Aug ’24 | €27.22 | €30.78 +13.1% | 19.9% | €50.00 | €22.00 | €12.74 | 18 |
| Jul ’24 | €25.49 | €32.63 +28.0% | 21.9% | €53.00 | €22.00 | €14.25 | 16 |
| Jun ’24 | €26.37 | €33.25 +26.1% | 21.8% | €53.00 | €22.00 | €18.09 | 16 |
| May ’24 | €29.30 | €34.13 +16.5% | 20.7% | €53.00 | €25.00 | €20.98 | 15 |
| Apr ’24 | n/a | €34.06 0% | 20.2% | €53.00 | €25.00 | €20.17 | 16 |
| Mar ’24 | n/a | €34.12 0% | 19.5% | €53.00 | €25.00 | €19.39 | 17 |
| Feb ’24 | €34.46 | €34.65 +0.5% | 19.4% | €53.00 | €25.00 | €21.06 | 17 |
| Jan ’24 | €34.56 | €35.78 +3.5% | 21.8% | €54.00 | €25.00 | €25.01 | 18 |
| Dec ’23 | €34.69 | €35.83 +3.3% | 21.8% | €54.00 | €25.00 | €24.80 | 18 |
| Nov ’23 | €33.15 | €35.78 +7.9% | 21.8% | €54.00 | €25.00 | €22.46 | 18 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Freeport-McMoRan
US$62.8b
Engages in the mining of mineral properties in North America, South America, and Indonesia.
FCX
US$42.16
7D
3.7%
1Y
26.6%
Aluminum Corporation of China
HK$126.4b
Primarily engages in the exploration and mining of bauxite, coal, and other resources in the People's Republic of China and internationally.
AOC
HK$0.58
7D
-2.7%
1Y
25.2%
LANXESS
€2.0b
Operates as a specialty chemicals company that engages in the development, manufacture, and marketing of chemical intermediates, additives, specialty chemicals, and consumer protection products worldwide.
LXS
€23.62
7D
-0.5%
1Y
5.8%